Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies - Takeaways - MDSpire

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • By

  • Jiashun Li

  • Ainikaer Abulaiti

  • Deyu Li

  • Yan Zhao

  • Paerhati Wahafu

  • Maerdan Maimaitiming

  • Shi Qiu

  • Yuxiang Zhang

  • Yaqin An

  • Wenxing Wang

  • Liangquan Shi

  • Maihemuti Yakufu

  • Li Shu

  • Guohua Li

  • Zhen Liu

  • June 22, 2026

  • 0 min

Share

  • 1

    The article corrects the Funding statement related to the efficacy and safety of CD3 bispecific antibodies in multiple myeloma.

  • 2

    The original Funding statement contained errors that have been rectified in the published correction.

  • 3

    The corrected Funding statement includes additional funding sources not mentioned in the original version.

  • 4

    The correction does not alter the scientific conclusions of the study.

  • 5

    The article is authored by Li J and colleagues and published in Frontiers in Immunology.

Original Source(s)

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • by Jiashun Li, Ainikaer Abulaiti, Deyu Li, Yan Zhao, Paerhati Wahafu, Maerdan Maimaitiming, Shi Qiu, Yuxiang Zhang, Yaqin An, Wenxing Wang, Liangquan Shi, Maihemuti Yakufu, Li Shu, Guohua Li, Zhen Liu

  • June 22, 2026

Related Content

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Biology of p53 protein isoforms and their significance in hematological malignancies

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min